LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
Year: 2023
Type: conference-abstract
Source: Annals of Oncology
Institutions: NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Edith Cowan University, Hollywood Private Hospital, Westmead Hospital, Massachusetts General Hospital, UPMC Hillman Cancer Center, St John of God Subiaco Hospital, Washington University in St. Louis, California Pacific Medical Center, Sarah Cannon, Angeles Clinic and Research Institute, Yale Cancer Center, Yale University, Hackensack University Medical Center, University of Colorado Cancer Center, University of Colorado Anschutz, Princess Alexandra Hospital, Metro South Health, Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, Melanoma Institute Australia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Moffitt Cancer Center, Regeneron Pharmaceuticals, Exelixis, Les Laboratories Pierre Fabre, Astex Pharmaceuticals, Tizona Therapeutics, Foghorn Therapeutics, BeiGene, Incyte, Moderna, G1 Therapeutics, Castle Biosciences, Eisai, Astellas Pharma, Qbiotics, Mereo BioPharma, Genentech, EMD Serono
OpenAlex ID: W4387809681